EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real‐life national setting over a decade

Coline Ducrot, Derek Dinart, Mathilde Reich, Max Piffoux, Maeva Bonneau, Mathieu Larroquette iD, Simon Nannini, Juliane Berchoud, Helène Bellio, Gregory Cherrier, Berengère Narciso, Axel Le Cesne und 11 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70023 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Coline Ducrot und 22 weiteren Autor:innen. Beteiligte Einrichtung: Centre Léon Bérard, Lyon, France. Hauptthemen laut MEDLINE: Chondrosarcoma, Bone Neoplasms. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Bayer, Institut National Du Cancer, Bayer Portugal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic chondrosarcoma (MCS) has a poor prognosis, and treatment options are scarce in this rare disease. This multicenter observational study provides real‐world data on treatment patterns of patients with MCS in France. Treatment characteristics, outcomes in terms of time to next treatment (TTNT) and overall survival (OS), and prognostic factors of patients ≥12‐year‐old treated for a MCS in nine French reference network centers were retrieved from the French Sarcoma Group prospective database. From 2008 to 2018, 127 patients with MCS were included, 31 were metastatic from diagnosis (synchronous cohort), 89 had a metastatic relapse, and 7 had locally advanced unresectable disease, of whom 4 developed secondary metastases (metachronous cohort). Median age at diagnosis was 61 years (14–90), 58.9% of patients received a systemic treatment with a median of 2 lines (1–6), 40.3% had a locoregional procedure on metastasis, and 9.7% of patients participated in a clinical trial at least once in the metastatic setting. Median OS from metastatic diagnosis was 12.7 months [95%CI 8.2, 14.9], without significant difference between the metachronous and synchronous cohorts. Median TTNT was 4.6 months [95%CI 3.0, 5.9], 3.4 months [95%CI 2.7, 4.8], and 3.4 months [95%CI 2.0, 7.9] in first, second, and third lines, respectively. In MCS, benefits of chemotherapies are very limited. Tyrosine kinase inhibitors such as regorafenib or pazopanib show some activity from first line. Locoregional treatment of metastasis is associated with survival and should be proposed when feasible. Inclusion in clinical trials should be prioritized.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaBone NeoplasmsHumansMaleFemaleAgedMiddle AgedAged, 80 and overAdultFranceAdolescentYoung AdultPrognosisNeoplasm MetastasisTreatment OutcomeProspective StudiesIndazolesPyrimidinesSulfonamides

Stichwörter der Autor:innen

clinical trialslocoregional treatmentmetastatic chondrosarcomaprognostic factorssystemic treatment

Substanzen

pazopanibIndazolesPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Centre Léon Bérard, Lyon, France.
  • Centre de Recherche en Cancérologie de Lyon (CRCL), équipe mort cellulaire et cancer de l'enfant, Lyon, France.
  • Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.
  • Institut Bergonié, Bordeaux, France.
  • Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Bordeaux, France.
  • University of Bordeaux, BPH, Epicene Team, UMR, Bordeaux, France.

ORCID-Profile: Mathieu Larroquette, Pascaline Boudou-Rouquette, Maud Toulmonde

Förderung

  • Bayer
  • Institut National Du Cancer
  • Bayer Portugal

Zitieren

APA

Ducrot, C., Dinart, D., Reich, M., Piffoux, M., Bonneau, M., Larroquette, M., Nannini, S., Berchoud, J., Bellio, H., Cherrier, G., Narciso, B., Le Cesne, A., Bompas, E., Gantzer, J., Valentin, T., Anract, P., de Percin, S., Boudou-Rouquette, P., de Pinieux, G., …, & Toulmonde, M. (2025). Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real‐life national setting over a decade. International Journal of Cancer. https://doi.org/10.1002/ijc.70023

Vancouver

Ducrot C, Dinart D, Reich M, Piffoux M, Bonneau M, Larroquette M, et al. Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real‐life national setting over a decade. International Journal of Cancer. 2025. doi:10.1002/ijc.70023

BibTeX
@article{Ducrot2025,
  author = {Ducrot, Coline and Dinart, Derek and Reich, Mathilde and Piffoux, Max and Bonneau, Maeva and Larroquette, Mathieu and Nannini, Simon and Berchoud, Juliane and Bellio, Helène and Cherrier, Gregory and Narciso, Berengère and Le Cesne, Axel and Bompas, Emmanuelle and Gantzer, Justine and Valentin, Thibaud and Anract, Philippe and de Percin, Sixtine and Boudou-Rouquette, Pascaline and de Pinieux, Gonzague and Gouin, Francois and Brahmi, Mehdi and Bellera, Carine and Toulmonde, Maud},
  title = {Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real‐life national setting over a decade},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70023}
}
Kostenlos starten →